With Lumasiran Pediatric Data, Alnylam Hopes For Approvals In All PH1 Patients
Executive Summary
Alnylam shows that lumasiran offers similar safety and efficacy in primary hyperoxaluria type 1 patients who are six or younger as it does in older patients. US and EU regulatory decisions loom.
You may also be interested in...
Alnylam Turns To Value-Based Pricing Again For Oxlumo
As with its first two approved RNAi therapies, Alnylam will negotiate value-based agreements with payers, but for Oxlumo, approved in pediatric patients, it will offer a patient need adjustment.
2020 Deal-Making Snapshot: A Busy Year For Bolt-Ons
Looking back at the deal landscape of 2020, large-scale deals were overtaken by smaller transactions, though volume was up, driven by pandemic-related business.
Intercept Commits To Resubmitting NASH NDA, But Analysts See Conflicting Signs
CEO Durso says Intercept is aiming to refile its NDA by end of 2021, but several departures in recent months indicate pessimism on NASH prospects to some analysts.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports